A clinical trial shows the neuroprotective effect of lixisenatide, a GLP-1 receptor agonist. Its use during a year prevented patients from getting worse, in what has been described as limited but promising benefits
Co-funded trial shows promise for Sanofi s diabetes drug in early Parkinson s disease pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Diabetes drug lixisenatide could slow down progression of Parkinson s disease, a development that s considered a significance step in the disease s management. | Health